Insider selling
Traded Mar 23 · filed 1 day laterNot reported under a pre-arranged trading plan
Viatris's See Remarks sold $284K of Viatris shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 3, 2025 · Filed Mar 10, 2026
A Viatris director paid $2.2K out of pocket for Viatris shares. Shares held went up 22% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$2,221
Shares × reported transaction price
<$25K
+22.0%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 3 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 1 earlier confirmed purchase
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
88 days after results of Aug 7, 2025, 3 days before results of Nov 6, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $10.53 on Nov 3, 2025, 45% above its 52-week low and 21% below its high, after an 8% rise over the previous 30 trading days
52-week range $7.26 (Apr 10, 2025) to $13.37 (Nov 22, 2024), 54% of the way up, from 250 adjusted closes. 30 trading days earlier: $9.79 on Sep 22, 2025. Describes the past only, not a forecast
RSI 64, 11% above its 200-day average, 4% above its 50-day average, 21% below the 52-week high, 20-day volatility 17% a year, against the S&P 500: +1 points over 1 month, +8 points over 3 months, +1 points over 6 months
From the adjusted closes up to Nov 3, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Bought 88 days after VTRS's last results announcement; 79% of its insiders' purchases since 2020 were made within 30 days after one. Traded 3 days before VTRS reported its results (Nov 6, 2025)
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
FDA approved Linagliptin on Nov 3, 2025, the same day as this trade.
Generic drug approved. Active ingredient: Linagliptin. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.6% | −2.2% | +0.6% |
| 30 days | −3.6% | +0.5% | −4.0% |
| 90 days | +16.0% | +9.0% | +7.0% |
| 180 days | +18.9% | +13.3% | +5.7% |
Past results only. Not a forecast.
Insider selling
Traded Mar 23 · filed 1 day laterNot reported under a pre-arranged trading plan
Viatris's See Remarks sold $284K of Viatris shares. The filing does not indicate a pre-arranged trading plan.
Insider filing
Traded Mar 6 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Mar 6 · filed 4 days later
Routine share withholding; mechanical by default.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.